Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review
Cyrus Jalili, Amir Kiani, Mohammadreza Gholami, et al.
IET Nanobiotechnology (2023) Vol. 17, Iss. 3, pp. 154-170
Open Access | Times Cited: 19

Showing 19 citing articles:

Resveratrol Activates Antioxidant Protective Mechanisms in Cellular Models of Alzheimer’s Disease Inflammation
Clara Bartra, Yi Yuan, Kristijan Vuraić, et al.
Antioxidants (2024) Vol. 13, Iss. 2, pp. 177-177
Open Access | Times Cited: 17
Unraveling the therapeutic efficacy of resveratrol in Alzheimer’s disease: an umbrella review of systematic evidence
Ali Azargoonjahromi, Fatemeh Abutalebian
Nutrition & Metabolism (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 15
Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression
Shaikh Sheeran Naser, Dibyangshee Singh, Subham Preetam, et al.
Materials Today Bio (2023) Vol. 21, pp. 100701-100701
Open Access | Times Cited: 16
Advancements in neurotherapeutics: nanoparticles overcoming the blood–brain barrier for precise CNS targeting
Alaa Alqudah, Alaa A. A. Aljabali, Omar Gammoh, et al.
Journal of Nanoparticle Research (2024) Vol. 26, Iss. 6
Closed Access | Times Cited: 6
Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy
Emma Ortiz, Pedro Montes, Citlali Ekaterina Rodríguez-Pérez, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 128-128
Open Access
Understanding of Alzheimer's Disease Pathophysiology for Therapeutic Implications of Natural Products as Neuroprotective Agents
Sneh Prabha, Arunabh Choudhury, Asimul Islam, et al.
Ageing Research Reviews (2025), pp. 102680-102680
Closed Access
Identification of potential inhibitors of Fyn-Kinase from bioactive phytochemicals of Berberis lycium for therapeutic targeting of neurodegenerative disease
Sneh Prabha, Arunabh Choudhury, Juhi Saraswat, et al.
Journal of Biomolecular Structure and Dynamics (2025), pp. 1-18
Closed Access
Could Metformin and Resveratrol Support Glioblastoma Treatment? A Mechanistic View at the Cellular Level
Raghad Sabaawi Ibrahim, Shahad Sabaawi Ibrahim, Ahmed El-Naas, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3368-3368
Open Access | Times Cited: 9
Evolution of lipid nanoparticles as charioteers of Alzheimer's disease therapeutics
Brati Chakraborty, Gayatri Patel, Bandana Padhan, et al.
Applied Materials Today (2024) Vol. 41, pp. 102442-102442
Closed Access | Times Cited: 2
De novo hyaluronic acid-based biomaterial: a promising perspective to manage neurodegenerative diseases
Somayeh Kakehbaraei, Morteza Arab‐Zozani, Seyran Kakebaraei
International Journal of Polymeric Materials (2024), pp. 1-15
Closed Access | Times Cited: 1
Oral administration of crocin-loaded solid lipid nanoparticles inhibits neuroinflammation in a rat model of epileptic seizures by activating SIRT1 expression
Seyran Kakebaraei, Mohammadreza Gholami, Touraj Zamir Nasta, et al.
Research in Pharmaceutical Sciences (2024) Vol. 19, Iss. 4, pp. 397-414
Open Access | Times Cited: 1
Nanoparticle-based flavonoid therapeutics: Pioneering biomedical applications in antioxidants, cancer treatment, cardiovascular health, neuroprotection, and cosmeceuticals
Hadeer M. Morsy, Mohamed Y. Zaky, Nour Y. S. Yassin, et al.
International Journal of Pharmaceutics (2024), pp. 125135-125135
Closed Access | Times Cited: 1
Phytoactive drugs used in the treatment of Alzheimer’s disease and dementia
Anshita Gupta Soni, Astha Verma, Renjil Joshi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 11, pp. 8633-8649
Closed Access
Protective effect of crocin-loaded nanoparticles in rats following epileptic seizures: Biochemical, behavioral and histopathological outcomes
Cyrus Jalili, Mohammadreza Gholami, Seyran Kakebaraei
Heliyon (2024) Vol. 10, Iss. 16, pp. e36122-e36122
Open Access
Development, Statistical Optimization, and Characterization of Resveratrol‐Containing Solid Lipid Nanoparticles (SLNs) and Determination of the Efficacy in Reducing Neurodegenerative Symptoms Related to Alzheimer’s Disease: In Vitro and In Vivo Study
Mohammad Amin Khishvand, Ehsan Mehrabani Yeganeh, Mohammad Zarei, et al.
BioMed Research International (2024) Vol. 2024, Iss. 1
Open Access
Sirtuin Proteins and Memory: A Promising Target in Alzheimer’s Disease Therapy?
Francesca Fernandez, Lyn R. Griffiths, Heidi G. Sutherland, et al.
Nutrients (2024) Vol. 16, Iss. 23, pp. 4088-4088
Open Access
Nanomedicine in the treatment of Alzheimer’s disease: bypassing the blood-brain barrier with cutting-edge nanotechnology
Nana Dong, Payam Ali‐Khiavi, Nima Ghavamikia, et al.
Neurological Sciences (2024)
Closed Access
The Potential Application of Resveratrol and Its Derivatives in Central Nervous System Tumors
Agnieszka Nowacka, Martyna Śniegocka, Wojciech Smuczyński, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13338-13338
Open Access
Page 1

Scroll to top